Clinical Trials

Cholangiocarcinoma

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

60 enrolled

Other solid neoplasm

Solid Tumors

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT07290894 2025-12-18

MITO VULVA-01

80 enrolled

Gynecologic

Vulvar Neoplasms

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

36 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

28 enrolled

Gynecologic

Advanced Endometrial Cancer

NCT07263360 2025-12-04

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

29 enrolled

BTC

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

48 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07014150 2025-06-10

Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT06984718 2025-05-22

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

120 enrolled

Carcinoma, Hepatocellular

NCT06919848 2025-04-09

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

74 enrolled

Biliary Tract Neoplasms

NCT06884982 2025-03-19

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

Carcinoma, Hepatocellular

NCT05195294 2025-03-10

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

55 enrolled

Hepatitis B, Carcinoma, Hepatocellular

NCT06849492 2025-02-27

SHIFT-001

120 enrolled

Breast

Advanced Triple Negative Breast Cancer

NCT06748508 2024-12-27

FDZL-GC003

141 enrolled

Stomach Neoplasms

NCT06648525 2024-10-18

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

68 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06389500 2024-04-29

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

NCT06253598 2024-03-07

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients